Mometazona Atb (Mometasone Furoate)

Mometasone Furoate, the active ingredient in Mometazona Atb, is a corticosteroid presented as a topical formulation for skin use. It treats inflammatory skin conditions such as eczema, psoriasis and dermatitis in both adults and children.

GNH USA supplies Mometazona Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometazona Atb is a topical corticosteroid used to manage inflammatory skin disorders.

- Eczema: reduces redness, itching and swelling associated with atopic dermatitis. - Psoriasis: helps clear plaques and diminishes scaling and inflammation. - Dermatitis: alleviates symptoms of contact and seborrheic dermatitis by suppressing local immune responses.

Topical application of Mometazona Atb may cause local skin reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Itching or mild irritation. - Dryness or peeling of the skin. - Erythema or mild redness. - Folliculitis or small pustules. - Pruritus.

Serious or Rare Side Effects: - Skin atrophy or thinning. - Telangiectasia (visible small blood vessels). - Secondary bacterial, fungal or viral infection. - Systemic adrenal suppression with extensive use. - Allergic contact dermatitis or hypersensitivity reactions. - Delayed wound healing.

Before using Mometazona Atb, consider the following safety measures. - Duration of Use: limit treatment to the shortest period necessary, typically no longer than 2‑4 weeks. - Occlusive Dressings: avoid covering treated areas with airtight dressings unless directed by a clinician. - Infected Skin: do not apply to skin with active bacterial, viral or fungal infections without medical advice. - Broken Skin: avoid use on open wounds, abrasions or severe eczema lesions. - Pediatric Use: use with caution in children; monitor for growth‑related side effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometazona Atb may interact with other medications applied to the skin or systemic agents.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use can increase risk of systemic adrenal suppression. - Potent CYP3A4 inhibitors applied topically: may raise local drug concentration. - Live vaccines: topical steroids may diminish local immune response to vaccination sites.

Moderate Interactions (Monitor Closely): - Topical antibiotics or antifungals: monitor for additive irritation. - Other topical steroids: avoid overlapping applications to reduce cumulative potency. - Immunosuppressants: may enhance immunosuppressive effect on skin. - Skin care products containing alcohol or astringents: can increase irritation risk.